Brief: Arcutis Highlights 2026 Strategic Priorities And Anticipated Milestones
12/01/2026 13:26
Jan 12 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O: ARCUTIS HIGHLIGHTS 2026 STRATEGIC PRIORITIES AND ANTICIPATED MILESTONES ARCUTIS BIOTHERAPEUTICS INC - TOPLINE RESULTS FROM INTEGUMENT-INFANT PHASE 2 STUDY EXPECTED Q1 2026 Source text: ID:nGNX8p3PSW Further company coverage: ARQT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Canada Przoryve Cream 0.05% Receives Health Canada Approval For Atopic Dermatitis
Arcutis Biotherapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Arcutis Q2 revenue rises on demand for ZORYVE, lifts 2026 sales outlook
Arcutis Biotherapeutics Inc expected to post earnings of 4 cents a share - Earnings Preview
Brief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4